Deflazacort

Bezeichnung:Deflazacort

CAS-Nr14484-47-0

Englisch Name:Deflazacort

CBNumberCB8705963

SummenformelC25H31NO6

Molgewicht441.52

MOL-Datei14484-47-0.mol

Synonyma

Deflazacort

Deflazacort physikalisch-chemischer Eigenschaften

Schmelzpunkt	255-256.5°C
alpha	D +62.3° (c = 0.5 in chloroform)
Siedepunkt	595.4±50.0 °C(Predicted)
Dichte	1.41
storage temp.	2-8°C
Löslichkeit	DMSO: ≥20mg/mL
pka	14.30±0.70(Predicted)
Aggregatzustand	powder
Farbe	white to tan
Merck	14,2862
InChIKey	FBHSPRKOSMHSIF-UBRVQRTASA-N
SMILES	C12(C(COC(C)=O)=O)[C@]3(C)C(C4C([C@H](C3)O)[C@]3(C)C(=CC(C=C3)=O)CC4)CC1OC(C)=N2

Sicherheit

S-Sätze:	24/25
WGK Germany	3
RTECS-Nr.	TU4157050
HS Code	29349990
Toxizität	LD50 orally in mice: 5200 mg/kg (Schiatti)

Gefahreninformationscode (GHS)

Deflazacort Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Deflazacort is an antiinflammatory treatment of rheumatoid arthritis. Its antirheumatic potency i s similar to that of prednisone, while its hyperglycernic and calcium depleting effects are reportedly less.
Chemische Eigenschaften
Off-White to Pale Yellow Solid
Originator
Dow Lepetit (Italy)
Verwenden
A systemic corticosteroid. A derivative of prednisolone. Used for rheumatoid arthritis and lupus
Verwenden
antiinflammatory
Verwenden
Deflazacort-d3, is the labeled analogue of Deflazacort (D228975), a systemic corticosteroid, and a derivative of prednisolone. Used for rheumatoid arthritis and lupus.
Definition
ChEBI: Deflazacort is a corticosteroid hormone.
Trademarks
LANTADIN; DEFLAN
Biochem/physiol Actions
Deflazacort is an anti-inflammatory and immunosuppressant glucocorticoid.
Clinical Use
Glucocorticoid:
Suppression of inflammatory and allergic disorders
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Aldesleukin: avoid concomitant use
Antibacterials: metabolism accelerated by rifamycins; metabolism possibly inhibited by erythromycin; concentration of isoniazid possibly reduced.
Anticoagulants: efficacy of coumarins and phenindione may be altered.
Antiepileptics: metabolism accelerated by carbamazepine, fosphenytoin, phenobarbital, phenytoin and primidone
Antifungals: increased risk of hypokalaemia with amphotericin - avoid; metabolism possibly inhibited by itraconazole and ketoconazole
Antivirals: concentration possibly increased by ritonavir.
Ciclosporin: rare reports of convulsions in patients on ciclosporin and high-dose corticosteroids; increased half-life of deflazacort.
Cobicistat: concentration increased by cobicistat - avoid.
Diuretics: enhanced hypokalaemic effects of acetazolamide, loop diuretics and thiazide diuretics.
Vaccines: high dose corticosteroids can impair immune response to vaccines; avoid with live vaccines.
Stoffwechsel
Deflazacort is immediately converted by plasma esterases to the pharmacologically active metabolite (D 21-OH). It is 40% protein-bound and has no affinity for corticosteroid-binding-globulin (transcortin). Elimination takes place primarily through the kidneys; 70% of the administered dose is excreted in the urine. The remaining 30% is eliminated in the faeces. Metabolism of D 21-OH is extensive; only 18% of urinary excretion represents D 21-OH. The metabolite of D 21-OH, deflazacort 6-beta-OH, represents one third of the urinary elimination.

Deflazacort Upstream-Materialien And Downstream Produkte

Deflazacort Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

14484-47-0, Deflazacort Verwandte Suche:

Send Inquriy